Table 3.

Summary of GH, IGF-1 and serum lanreotide levels throughout the study (ITT population)

Variable	Control group (n = 15)	Test group (n = 15)	Median difference between treatment groups (95% CI)
GH level (µg/l)
Baseline
Mean (SD)	2·22 (2·94)	2·49 (1·81)
Median	1·28	2·02
Study Completion
Mean (SD)	1·88 (1·87)	2·27 (1·82)
Median	1·29	1·94
Change from Baseline
Mean (SD)	–0·34 (1·63)	–0·23 (1·79)
Median	0·02	–0·23	–0·28 (–1·36 to –0·39)
IGF-1 (% ULN)
Baseline
Mean (SD)	115 (55)	112 (72)
Median	137	94
Study Completion
Mean (SD)	111 (53)	96 (53)
Median	119	85
Change from Baseline
Mean (SD)	–4 (17)	–16 (28)
Median	–5	–11	–8 (–24 to –9)
Serum lanreotide (µg/l)
Baseline
Mean (SD)	3·26 (1·52)	2·60 (1·13)
Median	2·83	2·62
Study Completion
Mean (SD)	2·73 (1·42)	2·89 (1·20)
Median	2·39	2·55
Change from Baseline
Mean (SD)	–0·76 (1·83)	0·16 (1·11)
Median	–0·71	0·32	0·89 (–0·21 to –1·74)

ITT, intention to treat; SD, standard deviation; ULN, upper limit of normal; 95% CI, 95% confidence interval.